GSK Urges Regulatory Changes To Pull EU Market From Doldrums
This article was originally published in The Tan Sheet
Executive Summary
The time appears right for Rx-to-OTC switches as European Union members struggle to control expanding health budgets in the face of aging populations and the continuing global economic crisis.
You may also be interested in...
GlaxoSmithKline's OTC Garage Sale Includes alli, FiberChoice
GlaxoSmithKline includes the alli weight-loss brand in its planned divestment of international OTCs worth about $813 million in 2010 sales, or 10% of the firm's total Consumer Healthcare business.
People In Brief
Mackenzie leads GSK Consumer in U.S.
EU Centralized Switch Process Needs Longer Exclusivity, More Trust - Execs
Limited data protection and a lack of trust between industry and regulators are dampening enthusiasm for the European Union's centralized switch process, according to industry leaders